HDBuzz

Website

Huntington's Disease research news. In plain language. Written by scientists. For the global HD community.

09/30/2026

uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced.

We unpack the hopeful but complex results in this article → https://en.hdbuzz.net/amt-130-at-four-years-hopeful-signs-complex-controls/

09/28/2026

September brought progress across the Huntington’s disease research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in HD research.

Full article here → https://en.hdbuzz.net/september-2026-this-month-in-huntingtons-disease-research/

09/24/2026

The CAG repeat that causes Huntington’s disease (HD) has a tendency to grow with age, but huntingtin is not the only gene containing an unstable genetic stutter. So scientists analyzed the genomes of more than 900,000 people to investigate the behavior of other DNA repeats. Their findings revealed that repeat expansions are widespread and may be controlled by similar molecular pathways.

To find out more, read the full article here → https://en.hdbuzz.net/studying-stutters-what-900000-genomes-teach-us-about-growing-dna-repeats/

09/21/2026

Unique research highlights an overlooked mental health disparity among Indigenous North American people with Huntington’s disease (HD) - and the need for care grounded in trust, community partnership, and cultural understanding.

Read more here: https://en.hdbuzz.net/highlighting-mental-health-disparities-in-indigenous-communities-affected-by-huntingtons-disease/

09/16/2026

Skyhawk Therapeutics shared data for SKY-0515, an experimental once-daily pill that targets both huntingtin and somatic instability, making it a possible “two-for-one” drug to treat HD.

Read more about this exciting news on HDBuzz → https://en.hdbuzz.net/encouraging-news-from-skyhawk-as-sky-0515-phase-1-2-data-continues-to-hold-promise/

09/14/2026

What if nutrition is one of the warning lights we should be checking earlier in Huntington’s disease? New research suggests simple nutrition measures may help identify when people with HD need extra support.

https://en.hdbuzz.net/food-for-thought-the-importance-of-nutrition-in-huntingtons-disease/

09/10/2026

A review of 23 studies found that EEG changes were linked to disease progression and clinical measures in Huntington’s disease (HD). While more research is needed, EEG holds potential to become a simple, non-invasive biomarker for monitoring HD over time.

Read the full article here → https://en.hdbuzz.net/could-brain-waves-help-track-huntingtons-disease/

09/07/2026

Five Huntington’s disease (HD) researchers discuss the cutting-edge techniques driving their work. From reading DNA molecule by molecule to visualizing proteins and neurons in remarkable detail, these technologies are giving scientists an increasingly complete picture of how HD begins and progresses.

Full article here → https://en.hdbuzz.net/hot-techniques-in-hd-research/

09/03/2026

What if Huntington’s disease (HD) changes how we “see” the world before we even notice symptoms? New research suggests visual thinking skills may help track HD progression.

https://en.hdbuzz.net/keeping-an-eye-on-hd-can-visual-thinking-skills-help-track-disease-progression/

09/02/2026

uniQure has submitted AMT-130 for regulatory approval in the US and UK. This drug is NOT yet approved; regulators must now review the evidence. Read more about this milestone here -> https://uniqure.gcs-web.com/node/12991/pdf and on HDBuzz here -> https://en.hdbuzz.net/the-other-shoe-drops-uniqure-shares-plans-to-submit-licensing-application-with-the-fda-for-amt-130/

Address

601 West 168th Street, Suite 54
New York, NY
10032

Website

https://hdbuzz.net/

Alerts

Be the first to know and let us send you an email when HDBuzz posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.